{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:15:10Z","timestamp":1788023710718,"version":"build-2784847793"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jaad.2020.03.073","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T19:27:22Z","timestamp":1585855642000},"page":"151-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Treatment of erythrodermic psoriasis with biologics: A systematic review"],"prefix":"10.1016","volume":"83","author":[{"given":"Osward Y.","family":"Carrasquillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Pab\u00f3n-Cartagena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre A.","family":"Falto-Aizpurua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marely","family":"Santiago-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina J.","family":"Cancel-Artau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Arias-Berrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael F.","family":"Mart\u00edn-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jaad.2020.03.073_bib1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2230.2001.00832.x","article-title":"Psoriasis\u2014epidemiology and clinical spectrum","volume":"26","author":"Christophers","year":"2001","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.03.073_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/01.ASW.0000429778.10020.67","article-title":"A review of the clinical variants and the management of psoriasis","volume":"26","author":"Ladizinski","year":"2013","journal-title":"Adv Skin Wound Care"},{"key":"10.1016\/j.jaad.2020.03.073_bib3","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(03)12954-6","article-title":"Psoriasis","volume":"361","author":"Lebwohl","year":"2003","journal-title":"Lancet"},{"issue":"4-5","key":"10.1016\/j.jaad.2020.03.073_bib4","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2020.03.073_bib5","first-page":"93","article-title":"Erythrodermic psoriasis: pathophysiology and current treatment perspectives","volume":"6","author":"Singh","year":"2016","journal-title":"Psoriasis (Auckl)"},{"issue":"4","key":"10.1016\/j.jaad.2020.03.073_bib6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaad.2009.05.048","article-title":"Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation","volume":"62","author":"Rosenbach","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.03.073_bib7","first-page":"342","article-title":"Biologic therapy in erythrodermic and pustular psoriasis","volume":"13","author":"Levin","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.03.073_bib8","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"3","author":"Moher","year":"2009","journal-title":"Open Med"},{"issue":"2","key":"10.1016\/j.jaad.2020.03.073_bib9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.pan.2017.02.008","article-title":"Frequency and prognosis of acute pancreatitis associated with fulminant or non-fulminant acute hepatitis A: a systematic review","volume":"17","author":"Haffar","year":"2017","journal-title":"Pancreatology"},{"key":"10.1016\/j.jaad.2020.03.073_bib10","author":"Wells","year":"2011"},{"issue":"11","key":"10.1016\/j.jaad.2020.03.073_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13120","article-title":"Secretory diarrhea and hypokalemia associated with colonic pseudo-obstruction: a case study and systematic analysis of the literature","volume":"29","author":"Bazerbachi","year":"2017","journal-title":"Neurogastroenterol Motil"},{"issue":"1","key":"10.1016\/j.jaad.2020.03.073_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.gie.2017.08.025","article-title":"Metal stents versus plastic stents for the management of pancreatic walled-off necrosis: a systematic review and meta-analysis","volume":"87","author":"Bazerbachi","year":"2018","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jaad.2020.03.073_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/gastro\/gox021","article-title":"Systematic review of mixed cryoglobulinemia associated with hepatitis E virus infection: association or causation?","volume":"5","author":"Bazerbachi","year":"2017","journal-title":"Gastroenterol Rep"},{"issue":"7","key":"10.1016\/j.jaad.2020.03.073_bib14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.pan.2017.08.012","article-title":"Systematic review of acute pancreatitis associated with interferon-\u03b1 or pegylated interferon-\u03b1: possible or definitive causation?","volume":"18","author":"Bazerbachi","year":"2018","journal-title":"Pancreatology"},{"issue":"1","key":"10.1016\/j.jaad.2020.03.073_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archdermatol.2007.28","article-title":"Systematic reviews: grading recommendations and evidence quality","volume":"144","author":"Robinson","year":"2008","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.03.073_bib16","first-page":"326","article-title":"Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade) [in Spanish]","volume":"134","author":"Mar\u00eda Del Pilar Vald\u00e9s","year":"2006","journal-title":"Rev Med Chil"},{"issue":"5","key":"10.1016\/j.jaad.2020.03.073_bib17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1590\/abd1806-4841.20176565","article-title":"Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis","volume":"92","author":"Arroyo-Tr\u00eddico","year":"2017","journal-title":"An Bras Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.03.073_bib18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/09546630310010895","article-title":"Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab","volume":"14","author":"Rongioletti","year":"2003","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.jaad.2020.03.073_bib19","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1365-2133.2007.08111.x","article-title":"Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis","volume":"157","author":"Takahashi","year":"2007","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.03.073_bib20","first-page":"247","article-title":"Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis","volume":"85","author":"Lisby","year":"2004","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2020.03.073_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1440-0960.2008.00463.x","article-title":"From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic\u00a0plaque psoriasis","volume":"49","author":"Yip","year":"2008","journal-title":"Australas J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.03.073_bib22","first-page":"644","article-title":"The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases","volume":"138","author":"O\u2019Quinn","year":"2002","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.03.073_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/ard.2003.014191","article-title":"Case number 29: hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade)","volume":"63","author":"Fiehn","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jaad.2020.03.073_bib24","first-page":"546","article-title":"Life-threatening pustular and erythrodermic psoriasis responding to infliximab","volume":"5","author":"Lewis","year":"2006","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.03.073_bib25","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/archderm.141.12.1607","article-title":"Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis","volume":"141","author":"Heikkil\u00e4","year":"2005","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.03.073_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2133.2006.07639.x","article-title":"A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity","volume":"156","author":"Poulalhon","year":"2007","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.03.073_bib27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1346-8138.2010.00971.x","article-title":"Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma","volume":"38","author":"Torii","year":"2011","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.03.073_bib28","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.radcr.2018.02.005","article-title":"Computed tomography imaging findings in erythrodermic psoriasis treated with infliximab: a case report","volume":"13","author":"Kurokawa","year":"2018","journal-title":"Radiol Case Rep"},{"issue":"3","key":"10.1016\/j.jaad.2020.03.073_bib29","doi-asserted-by":"crossref","first-page":"AB171","DOI":"10.1016\/j.jaad.2008.11.745","article-title":"Successful treatment of life-threatening erythrodermic psoriasis with infliximab","volume":"60","author":"Belinchon","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.03.073_bib30","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1440-0960.2008.00487.x","article-title":"Infliximab rescue of efalizumab withdrawal flare and psoriasis-precipitated depression","volume":"49","author":"Yip","year":"2008","journal-title":"Australas J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.03.073_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0213-9251(06)72498-4","article-title":"Infliximab: an alternative in refractory erythrodermic psoriasis","volume":"21","author":"Su\u00e1rez Pedreira","year":"2006","journal-title":"Piel"},{"issue":"3","key":"10.1016\/j.jaad.2020.03.073_bib32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000348645","article-title":"Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases","volume":"5","author":"Saraceno","year":"2013","journal-title":"Case Rep Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.03.073_bib33","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1684\/ejd.2014.2325","article-title":"Treatment of recalcitrant erythrodermic psoriasis with ustekinumab","volume":"24","author":"Stinco","year":"2014","journal-title":"Eur J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.03.073_bib34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jdermsci.2015.01.005","article-title":"Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis","volume":"78","author":"Pescitelli","year":"2015","journal-title":"J Dermatol Sci"},{"issue":"1","key":"10.1016\/j.jaad.2020.03.073_bib35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5021\/ad.2016.28.1.121","article-title":"Erythrodermic psoriasis improved by ustekinumab: a report of two cases","volume":"28","author":"Kim","year":"2016","journal-title":"Ann Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.03.073_bib36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/dth.12131","article-title":"Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission","volume":"27","author":"Koutsoukou","year":"2014","journal-title":"Dermatol Ther"},{"issue":"8","key":"10.1016\/j.jaad.2020.03.073_bib37","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1346-8138.2011.01499.x","article-title":"Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies","volume":"39","author":"Casti\u00f1eiras","year":"2012","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.03.073_bib38","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1365-2133.2010.09669.x","article-title":"Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies","volume":"162","author":"Santos-Juanes","year":"2010","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2020.03.073_bib39","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1346-8138.2011.01224.x","article-title":"Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series","volume":"38","author":"Wang","year":"2011","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.03.073_bib40","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1684\/ejd.2014.2386","article-title":"Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis","volume":"24","author":"Errichetti","year":"2014","journal-title":"Eur J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.03.073_bib41","doi-asserted-by":"crossref","first-page":"AB189","DOI":"10.1016\/j.jaad.2014.01.784","article-title":"Short-and long-term treatment of erythrodermic psoriasis with ustekinumab: a national and multicenter case series","volume":"70","author":"Concha-Garz\u00f3n","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2020.03.073_bib42","first-page":"S77","article-title":"Erythrodermic psoriasis and hepatitis C infection treated with pegylated interferon and anti-TNF\u03b1 \u03b1(etanercept) therapy","volume":"27","author":"Talat","year":"2017","journal-title":"J Coll Physicians Surg Pak"},{"issue":"6","key":"10.1016\/j.jaad.2020.03.073_bib43","first-page":"15","article-title":"Long-term management of erythrodermic psoriasis with anti-TNF agents","volume":"16","author":"Romero-Mat\u00e9","year":"2010","journal-title":"Dermatol Online J"},{"issue":"1","key":"10.1016\/j.jaad.2020.03.073_bib44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2133.2006.07217.x","article-title":"Treatment of erythrodermic psoriasis with etanercept","volume":"155","author":"Esposito","year":"2006","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2020.03.073_bib45","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0001-7310(07)70122-9","article-title":"Psoriatic erythroderma treated with etanercept [in Spanish]","volume":"98","author":"Piqu\u00e9-Duran","year":"2007","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"10.1016\/j.jaad.2020.03.073_bib46","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/bjd.16252","article-title":"Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series","volume":"178","author":"Weng","year":"2018","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2020.03.073_bib47","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1111\/jdv.14234","article-title":"Successful secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis","volume":"31","author":"Mugheddu","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2020.03.073_bib48","doi-asserted-by":"crossref","first-page":"e12607","DOI":"10.1111\/dth.12607","article-title":"Erythrodermic psoriasis and secukinumab: our clinical experience","volume":"31","author":"Mateu-Puchades","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2020.03.073_bib49","first-page":"1","article-title":"A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab","author":"Galluzzo","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.jaad.2020.03.073_bib50","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jdcr.2018.01.006","article-title":"Repigmentation and new growth of hairs after anti\u2013interleukin-17 therapy with\u00a0secukinumab for psoriasis","volume":"4","author":"Rongioletti","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.jaad.2020.03.073_bib51","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/qjmed\/hct139","article-title":"Erythrodermic psoriasis","volume":"107","author":"Mumoli","year":"2014","journal-title":"QJM"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2020.03.073_bib52","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1111\/j.1529-8019.2009.01266.x","article-title":"Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab","volume":"22","author":"Richetta","year":"2009","journal-title":"Dermatol Ther"},{"issue":"S4","key":"10.1016\/j.jaad.2020.03.073_bib53","first-page":"68","article-title":"Erythrodermic psoriasis successfully treated with adalimumab: a case study","volume":"27","author":"Vidal","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2020.03.073_bib54","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/1346-8138.13622","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume":"44","author":"Saeki","year":"2017","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.03.073_bib55","doi-asserted-by":"crossref","first-page":"446","DOI":"10.5021\/ad.2015.27.4.446","article-title":"Erythrodermic psoriasis treated with golimumab: a case report","volume":"27","author":"Lee","year":"2015","journal-title":"Ann Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.03.073_bib56","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/1346-8138.14294","article-title":"Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study","volume":"45","author":"Sano","year":"2018","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.03.073_bib57","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2133.2012.10940.x","article-title":"Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study","volume":"167","author":"Viguier","year":"2012","journal-title":"Br J Dermatol"},{"issue":"S6","key":"10.1016\/j.jaad.2020.03.073_bib58","first-page":"102","article-title":"Treatment of erythrodermic psoriasis with biological therapies in two cases","volume":"30","author":"Sahel","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220304965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220304965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:53:53Z","timestamp":1759272833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220304965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0190962220304965"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.03.073","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of erythrodermic psoriasis with biologics: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.03.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}